CASP3 and cancer: Furthermore, at submicromolar concentrations (0.36, 0.41 μM, respectively), the fused triazolopyridopyrimidine (64) showed greater efficacy against both cell lines, causing cell cycle arrest by increasing the cell cycle inhibitor p21 and cancer cell death by activating caspase-3 (Fig. 14).41